- Home
- BGLC vs BCLI Comparison
BGLC vs BCLI Comparison
Compare BGLC & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- BCLI
- Stock Information
- Founded
- BGLC 2017
- BCLI 2000
- Country
- BGLC Malaysia
- BCLI United States
- Employees
- BGLC N/A
- BCLI N/A
- Industry
- BGLC Medical Specialities
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BGLC Health Care
- BCLI Health Care
- Exchange
- BGLC Nasdaq
- BCLI Nasdaq
- Market Cap
- BGLC 10.7M
- BCLI 9.8M
- IPO Year
- BGLC N/A
- BCLI N/A
- Fundamental
- Price
- BGLC $5.14
- BCLI $1.17
- Analyst Decision
- BGLC
- BCLI
- Analyst Count
- BGLC 0
- BCLI 0
- Target Price
- BGLC N/A
- BCLI N/A
- AVG Volume (30 Days)
- BGLC 3.1M
- BCLI 395.1K
- Earning Date
- BGLC 08-13-2025
- BCLI 08-13-2025
- Dividend Yield
- BGLC N/A
- BCLI N/A
- EPS Growth
- BGLC N/A
- BCLI N/A
- EPS
- BGLC N/A
- BCLI N/A
- Revenue
- BGLC $9,265,870.00
- BCLI N/A
- Revenue This Year
- BGLC N/A
- BCLI N/A
- Revenue Next Year
- BGLC N/A
- BCLI N/A
- P/E Ratio
- BGLC N/A
- BCLI N/A
- Revenue Growth
- BGLC N/A
- BCLI N/A
- 52 Week Low
- BGLC $2.01
- BCLI $0.72
- 52 Week High
- BGLC $15.60
- BCLI $6.30
- Technical
- Relative Strength Index (RSI)
- BGLC 55.54
- BCLI 48.71
- Support Level
- BGLC $3.57
- BCLI $1.17
- Resistance Level
- BGLC $7.05
- BCLI $1.32
- Average True Range (ATR)
- BGLC 1.44
- BCLI 0.09
- MACD
- BGLC -0.04
- BCLI 0.00
- Stochastic Oscillator
- BGLC 25.00
- BCLI 50.00
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.